Abbie Celniker

Abbie Celniker is chairwoman of Goldfinch Bio and partner at Third Rock Ventures, where she focuses on the formation, development and strategy of Third Rock's portfolio companies. Abbie brings over 30 years of experience in R&D and senior leadership roles.

Prior to joining Third Rock Ventures, she served as president and CEO of Eleven Biotherapeutics since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion's executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals, Inc. and the vice president of protein technologies of the Wyeth Research facilities.

Abbie is the chair of MassBio's board of directors and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona.